TransMedics (TMDX) Current Deferred Revenue (2018 - 2026)

TransMedics' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 41.72% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 41.72% YoY), while the FY2025 annual figure was $2.9 million, up 66.76% from the prior year.
• Current Deferred Revenue was $2.9 million for Q1 2026 at TransMedics, up from $2.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $3.3 million in Q3 2025 to a low of $226000.0 in Q3 2022.
• Historically, Current Deferred Revenue has averaged $1.5 million across 5 years, with a median of $1.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue slumped 42.82% in 2022, then soared 1063.27% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $241000.0 in 2022, then soared by 713.69% to $2.0 million in 2023, then fell by 11.17% to $1.7 million in 2024, then soared by 66.76% to $2.9 million in 2025, then increased by 1.38% to $2.9 million in 2026.
• The last three Current Deferred Revenue figures came in at $2.9 million (Q1 2026), $2.9 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.